Rituximab in the Treatment of Interstitial Lung Diseases Related to Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis: A Systematic Review

OBJECTIVE: The effectiveness of rituximab in anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis (DM) with interstitial lung disease (ILD) has been explored only in isolated case reports and small series. This paper aims to review the current evidence regarding rituximab (RTX) use...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Chenjia, Li, Wenyu, Xie, Qibing, Yin, Geng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803653/
https://www.ncbi.nlm.nih.gov/pubmed/35116041
http://dx.doi.org/10.3389/fimmu.2021.820163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803653/
https://www.ncbi.nlm.nih.gov/pubmed/35116041
http://dx.doi.org/10.3389/fimmu.2021.820163

Ejemplares similares